Abstract: A hybridoma which produces monoclonal antibodies having a high affinity and selectivity for digoxin is produced by immunizing mice with digoxin, fusing the spleen cells from the treated mice with mice myeloma cells, separating hybrids from non-fused cells, selecting the hybrids which produce monoclonal antibodies directed against digoxin and isolating the hybrids.

Abstract: The compound of the formula ##STR1## and non-toxic, pharmacologically acceptable acid addition salts thereof. The compound as well as its salts are useful as analgesics.

Abstract: The invention relates to 5,6-dihydro-pyrrolo[2,1-a]isoquinolines of the formula ##STR1## wherein R, R.sup.2, R.sup.3, and R.sup.7, which may be identical or different, each represent a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms;R.sup.1 represents a cyano, hydroxycarbonyl, or alkoxycarbonyl group having from 1 to 4 carbon atoms or a primary or secondary, substituted or unsubstituted, aliphatic, cycloaliphatic, araliphatic, aromatic, or heterocyclic aminocarbonyl group;R.sup.4 and R.sup.8, which may be identical or different, each represent a hydrogen atom, a hydroxyl group, an alkoxy or alkylthio group having up to 4 carbon atoms, or an NR.sup.9 R.sup.10 group;R.sup.5 and R.sup.6, which may be identical or different, each represent a hydroxy atom or an alkoxy or alkylthio group having from 1 to 4 carbon atoms, or together represent an --O--CH.sub.2 --O--, --O--CH.sub.2 --CH.sub.2 --O--, or --O--CH.dbd.CH--O group;R.sup.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2, which may be identical to or different from each other, are each hydrogen, fluorine, chlorine, bromine, trifluoromethyl, hydroxyl, nitro, amino, cyano, methylsulfonamido, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 3 carbon atoms, (alkyl of 1 to 3 carbon atoms)thio or (alkanoyl of 2 to 4 carbon atoms)amino;R.sub.3 is hydrogen, fluorine, chlorine, bromine or alkyl of 1 to 3 carbon atoms;R.sub.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, alkyl of 1 to 6 carbon atoms or phenyl(alkyl of 1 to 6 carbon atoms);R.sub.2 is hydrogen, alkyl of 1 to 4 carbon atoms or phenyl(alkyl of 1 to 6 carbon atoms);R.sub.3 is hydrogen or alkyl of 1 to 6 carbon atoms;n and m are each independently 0, 1 or 2, the sum of n and m being 1 or 2;X, Y and Z are each independently oxygen, sulfur, --NR.sub.4 --, .dbd.CR.sub.5 --, --CHR.sub.5 --, ##STR2## provided that only one of X, Y and Z is O, S ##STR3## and one or two of X, Y and Z are --NR.sub.4 --; R.sub.4 is hydrogen or alkyl of 1 to 4 carbon atoms; andR.sub.5 is hydrogen or, together with a vicinal radical R.sub.5, a phenyl ring, or when m and n are both 1, the dihydro form with its double bond in conjugation with the C-terminal carboxylic group;or a non-toxic, pharmacologically acceptable salt thereof. The compounds as well as their salts are useful as antihypertensives.

Abstract: A novel divisible delayed release pharmaceutical tablet, wherein the rate of release of active ingredient is independent of the size and nature of the total surface area, and the fragments of which have the same characteristics of release of active ingredient as the undivided tablet.

Abstract: The invention relates to new substituted pyrrolidinones of general formula ##STR1## wherein R.sub.1 represents a phenyl group which may be mono- or di-substituted by methyl, methoxy, fluorine, chlorine, bromine or trifluoromethyl, or a pyridyl group;R.sub.2 represents hydrogen or a straight-chained or branched alkyl group with 1-4 carbon atoms;R.sub.3 represents a straight-chained or branched alkyl group with 1-3 carbon atoms, a hydroxyalkyl group with 2-3 carbon atoms, a phenyl group which can be mono- or di-substituted by chlorine, bromine, methyl or methoxy, a cyclohexyl group or a dialkylamino alkyl group, where in each alkyl group can contain from 1-3 carbon atoms;R.sub.4 represents hydrogen or a straight-chained or branched alkyl group with 1-3 carbon atoms; orR.sub.3 and R.sub.

Abstract: Compounds of the formula ##STR1## wherein one of R.sub.1 and R.sub.2 is hydrogen, halogen, methyl, methoxy, amino or nitro and the other is hydrogen; orR.sub.1 and R.sub.2 are both halogen;R.sub.3 is hydrogen, halogen or methyl;R.sub.4 and R.sub.5 are each independently hydrogen or alkyl or 1 to 2 carbon atoms; orR.sub.4 and R.sub.5, together with each other and the nitrogen atom to which they are attached, are pyrrolidino or morpholino; andX is --O--, --NH--, or --S--;and non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as their salts are useful anti-depressants.

Abstract: Compounds of the formula ##STR1## wherein Het is ##STR2## n is an integer from 1 to 4, inclusive, preferably 2 or 3, R.sub.1 is H or acyl,R.sub.2 is H, R.sub.1 O, --NHSO.sub.2 R.sub.7, --NHCOR.sub.8, --NHCONHR.sub.8, --NH--CH.sub.2 --C.sub.6 H.sub.4 --R.sub.9, --CH.sub.2 OH, --CH.sub.2 SO.sub.2 R.sub.7, --CONHR.sub.8, halogen or --CN,R.sub.3 is H, halogen, R.sub.7 or --OR.sub.7,R.sub.2 and R.sub.3 together with each other are ##STR3## R.sub.4 is H, --CH.sub.3 or --C.sub.2 H.sub.5, R.sub.5 and R.sub.6 are each H or --CH.sub.3,R.sub.7 is C.sub.1 -C.sub.4 alkyl,R.sub.8 is H or C.sub.1 -C.sub.4 alkyl,R.sub.9 is H, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy optionally interrupted by oxygen,R.sub.10 and R.sub.12 are each H, CH.sub.3, Cl or OCH.sub.3, or together methylenedioxy,X is ##STR4## or N, and Z is --CH.sub.2 or --CO;in the form of racemates, enantiomers, diastereoisomeric antipode pairs, and non-toxic, pharmacologically acceptable acid addition salts thereof.

Abstract: The invention describes the use of 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine and the acid addition salts thereof for the treatment of Parkinson's disease or Parkinsonism.

Abstract: The invention relates to 4-phenyl-tetrahydro-furano-pyridines of the formulas ##STR1## wherein R.sup.1 to R.sup.5 are variously defined. The compounds of the invention are intended to be used as anti-depressants with, in particular, thymoleptic and central-stimulant properties.

Abstract: The invention discloses a method of treating an individual having a disorder responsive to PAF-antagonist activity by treating the individual with a compound of formula I. ##STR1## wherein A is an anellated and optionally substituted benzene or 5- or 6- membered heterocyclic ring; R.sub.5 and Z are each independently hydrogen or an optionally substituted C.sub.1 -C.sub.8 alkyl, alkenyl or alkynyl; R.sub.6 is an optionally substituted phenyl, or is thienyl or .alpha.-pyridyl; Y is ##STR2## and nontoxic, pharmaceutically acceptable acid addition salts thereof.

Abstract: The invention discloses a method of treating an individual having a disorder responsive to PAF-antagonist activity by treating the individual with a compound of formula I or II ##STR1## wherein A is an anellated and optionally substituted benzene or 5- or 6-membered heterocyclic ring; R.sub.5 and Z are each independently hydrogen or an optionally substituted C.sub.1 -C.sub.8 alkyl, alkenyl or alkynyl; R.sub.6 is an optionally substituted phenyl, or is thienyl or is .alpha.-pyridyl; Y is CO, CS or CH.sub.2 ; and nontoxic, pharmaceutically acceptable acid addition salts thereof.

Abstract: The invention discloses a method of treating an individual having a disorder responsive to PAF-antagonist activity by treating the individual with a compound of formula I or II: ##STR1## wherein A is an annealed and optionally substituted benzene or 5- or 6-membered heterocyclic ring; B is an optionally substituted 5-membered heterocyclic ring; R.sub.5 and R.sub.7 are each independently hydrogen or an optionally substituted C.sub.1 -C.sub.8 alkyl, alkenyl or alkynyl; R.sub.6 is an optionally substituted phenyl, or is thienyl or .alpha.-pyridyl; and non-toxic, pharmaceutically acceptable acid addition salts thereof.

Abstract: The invention herein relates to novel quaternary 6,11-dihydro-dibenzo-[b,e]-thiepine-11-N-alkylnorscopine ethers, the preparation thereof, and their use as spasmolytics or bronchospasmolytics.

Abstract: A novel divisible delayed release pharmaceutical tablet, wherein the rate of release of active ingredient is independent of the size and nature of the total surface area, and the fragments of which have the same characteristics of release of active ingredient as the undivided tablet.

Abstract: Disclosed are novel compounds having the formula ##STR1## wherein R.sub.1 is a hydrogen or halogen atom, a lower alkyl, lower alkoxy, lower alkoxy lower alkyl, lower alkenyl, lower alkenyl oxy, cyano, hydroxy, trifluoromethyl, nitro, amino, aminocarbonylmethyl, lower monoalkylamino, lower dialkylamino group;R.sub.2 is a hydrogen or halogen atom, cyano, lower alkyl or lower alkoxy or acylamino group;R.sub.3 is a hydrogen or halogen atom, a lower alkyl or lower alkoxy group, while R.sub.2 and R.sub.3 together can also be a butadienyl or methylene dioxy group;R.sub.4 is a hydrogen atom or a lower alkyl group;R.sub.5 is a chlorine atom or a trifluoromethyl group;X is an alkylene group;and the non-toxic, pharmaceutically acceptable acid addition salts thereof.The compounds are suitable for treatment and prophylaxis of hypertension.

Abstract: Compounds of the formula ##STR1## wherein X, Y and Z are each independently hydrogen, halogen, lower alkyl, halo(lower alkyl), lower alkoxy, halo(lower alkoxy), (lower alkyl)thio or halo(lower alkyl)thio, orY and Z, together with each other, are lower alkylenedioxy;and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as analgesics.

Abstract: Compounds of the formula whereinHet is a heterocycle;n is an integer from 1 to 4, inclusive, preferably 2 or 3;R.sub.1 is H or acyl;R.sub.2 is H, R.sub.1 O, --NHSO.sub.2 R.sub.7, --NHCOR.sub.8, --NHCONHR.sub.8, --NH--CH.sub.2 --C.sub.6 H.sub.4 --R.sub.9, --CH.sub.2 OH, --CH.sub.2 SO.sub.2 R.sub.7, --CONHR.sub.8, halogen or --CN;R.sub.3 is H, halogen, R.sub.7 or --OR.sub.7 ; orR.sub.2 and R.sub.3, together with each other, are ##STR1## N.sub.4 is H, --CH.sub.3 or --C.sub.2 H.sub.5 ; R.sub.5 and R.sub.6 are each H or --CH.sub.3 ;R.sub.7 is C.sub.1 -C.sub.4 alkyl;R.sub.8 is H or C.sub.1 -C.sub.4 alkyl; andR.sub.9 is H, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy optionally interrupted by oxygen;and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as the salts are useful as bronchospasmolytics, spasmolytics, muscle-relaxants, antiallergics and hypotensives.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or alkyl of 1 to 4 carbon atoms; andR.sub.2 is pyridyl, phenyl or mono-, di- or tri-substituted phenyl, where the substituents are alkyl of 1 to 2 carbon atoms, alkoxy of 1 to 2 carbon atoms, fluorine, chlorine, bromine, trifluoromethyl, nitro, benzyloxy or hydroxyl.The compounds are useful as nootropics.